Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!

About | View Sample | Privacy

Hottest Products

Compare Top Solutions in:

Evaluate more than 400,000 products >>

Featured Jobs

Hematology Oncology Consultant, Hematology - Louisiana North Job
Celgene Corporation - Louisiana, LA, US
Associate Director, Global Production Planning & Inventory Control Job
Celgene Corporation - Basking Ridge, NJ, US
Principal Scientist
Watson Pharmaceuticals - Fort Lauderdale, FL
Manager, Strategic Forecasting & Analytics Job
Celgene Corporation - Basking Ridge, NJ, US
Patient Support Specialist Job
Celgene Corporation - Berkeley Heights, NJ, US

More Jobs >>

Events

New Paradigms to Fund & Move Biotech
January 11-12, 2012 — San Francisco, CA
Health Market Science Webinar: 3 Steps to New Physician Opportunities
Nov. 17
Life Science in the Cloud
Nov 16, 2011 — Cambridge, MA
Biomarker Applications for Improved Clinical Trial Outcomes
Nov. 15-16 — Boston

More Events >>

Related Tags >> peramivir

BioCryst News

Most Popular BioCryst Story

Vax crisis could spur swift peramivir approval

October 22, 2009 — 7:49am ET | By John Carroll

There's been a considerable amount of speculation about which of the new flu vaccine and antiviral technologies now in the clinic will benefit from the swine flu outbreak and the outcry it has Read more...

BioCryst Press Releases

BioCryst Announces Positive Top-Line Results from BCX4208 Phase 2B Gout Study in Patients Not Responding to Allopurinol Alone
Biocryst Pharmaceuticals (BCRX) Awarded Additional $55.0 Million by the Department of Health and Human Services to Complete Pera
Southern Research Expands Capabilities with Acquisition of BioCryst Pharmaceuticals Bioanalytical Lab Unit
BioCryst Reports Results from Two Forodesine Oncology Studies
BioCryst Reports Positive Results From A Phase 2 Study Of BCX4208 Combined with Allopurinol in Patients with Gout

Latest Headlines

Vax crisis could spur swift peramivir approval
October 22, 2009
BioCryst outlines Phase III plans for peramivir
October 1, 2009

Paid Research Reports

Trends in mHealth and Telemedicine
The Global Aesthetic Dermatology Market Outlook
Future Directions in Regenerative Medicine
Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

More Research Reports >>

THE FIERCEMARKETS NETWORK